Drug intelligence / Profile preview

AGS-534

Development stage: Preclinical
Lead developer: Neuromagen Pharma
Modality: Small Molecules
Administration: Subcutaneous

Overview

AGS-534 is a small molecule telomerase activator currently in preclinical development by Neuromagen Pharma. The compound functions by stimulating the activity of Telomerase Reverse Transcriptase (TERT), the catalytic subunit of the telomerase enzyme complex responsible for maintaining telomere length at chromosome ends. Telomerase activity typically declines with age, leading to cellular senescence and associated pathologies. By activating TERT, AGS-534 aims to restore telomere maintenance and improve cellular regenerative capacity. It is being investigated for potential therapeutic applications in fertility, specifically addressing ovarian aging, as well as in cardiovascular diseases.

Targets

TERT (Telomerase)

Beyond the preview

Go deeper on AGS-534.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGS-534.

Explore the full profile